# Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/

> **NIH NIH UM1** · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2022 · $71,500,000

## Abstract

Abstract
This supplement will support ACTIV-2D
ACTIV-2D is a master protocol to evaluate the safety and efficacy of investigational agents for the treatment of
symptomatic non-hospitalized adults with SARS-CoV-2 infection. The protocol is a phase III multicenter,
randomized, double blind trial to evaluate the safety and efficacy of S-217622 for the treatment of symptomatic
high-risk non-hospitalized adults with SARS-CoV-2 infection.
The primary outcome is to determine if the investigational agent (S-217622) will prevent the composite
endpoint of hospitalization due to any cause or death due to any cause through study Day 29. Hospitalization
is defined as ≥24 hours of acute care, in a hospital or similar acute care facility, including Emergency Rooms or
temporary facilities instituted to address medical needs of those with severe coronavirus disease 2019
(COVID-19) during the COVID-19 pandemic.

## Key facts

- **NIH application ID:** 10594377
- **Project number:** 3UM1AI068636-16S1
- **Recipient organization:** UNIVERSITY OF CALIFORNIA LOS ANGELES
- **Principal Investigator:** Judith S. Currier
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $71,500,000
- **Award type:** 3
- **Project period:** 2022-03-21 → 2023-05-02

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10594377

## Citation

> US National Institutes of Health, RePORTER application 10594377, Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/ (3UM1AI068636-16S1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10594377. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*